Short answer
Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on October 20, 2026 reporting Item 8.01 (Other Events). Casdatifan plus zimberelimab delivered 50% cORR and 69% 12-month PFS in first-line ccRCC.
Arcus Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Casdatifan plus zimberelimab delivered 50% cORR and 69% 12-month PFS in first-line ccRCC
- Casdatifan, ipilimumab and zimberelimab showed 4% primary progression after three months’ follow-up
- Second-line casdatifan plus cabozantinib produced 14.5-month median PFS and 44% cORR
- Late-line casdatifan monotherapy achieved 35-month median overall survival and 36% cORR
- Consistent safety findings across regimens support continued clinical development in ccRCC
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcus Biosciences, Inc. 8-K filings
Get the next RCUS 8-K as it lands
Follow RCUS for push alerts, or ask the research agent what this filing means.